Newson Clinic describes UK hormone-health consultations and names progesterone among the hormones it may prescribe. Its wording is relevant to someone researching micronised progesterone, but it does not establish a specific capsule catalog. In particular, a familiar UK brand should not be assigned to the clinic merely because a medicine-information page explains that brand.
We reviewed Newson’s consultation and public appointment information on September 29, 2026, together with separately identified UK product information. The distinction between those records is central to this review. The clinic’s offer concerns assessment and care; the product information describes one named medicine. Neither verifies an individual prescription, a dispensing pharmacy, a US service or personal suitability.
Read this article by section
The offer is a UK clinical consultation
Newson’s consultation page and main service information describe in-person and video appointments for hormone-related concerns. The listed locations include Stratford-upon-Avon, London and Hale. This is a relevant clinical offer, not merely a hormone education site. It is also a UK offer: video access should not be interpreted as worldwide prescribing or US medicine delivery. Our Alpha Hormones review illustrates a different published access boundary within the United States. A prospective patient should establish the applicable jurisdiction and clinician arrangements before comparing either service’s price or medicine language.
The hormone list does not specify a capsule brand
Newson’s service description names progesterone, estradiol and testosterone and uses body-identical terminology. Naming the hormone establishes a topic of care; it does not identify the route, brand, strength or complete formulation that would be proposed. The micronized meaning guide separates that processing term from other medicine details. British and US spelling differences do not bridge the missing product information. A question to the clinic should ask which exact preparation is proposed for the intended purpose, rather than assuming that every mention of progesterone refers to one familiar UK oral brand.
Utrogestan is a product example, not a Newson dispensing record
The reviewed UK Utrogestan 100 mg product information identifies Besins’ oral micronised progesterone capsules and describes use alongside estrogen for specified postmenopausal patients with a uterus. That information is about the named product. It does not verify that Newson prescribes it, that it is currently available from a selected pharmacy or that the clinic would recommend it to a particular patient. The route guide is useful here because a label’s route should stay attached to that preparation. No instruction from a separate vaginal product or another country’s label should be silently imported into this record. The NHS explanation of Utrogestan also distinguishes its oral menopause use from separate vaginal progesterone products used in fertility care. This does not establish Newson’s prescribing protocol. It illustrates why a search result containing the same hormone and a familiar brand family may still concern a different route and purpose. Bring the exact name and patient information into the discussion; do not infer that a label for one preparation authorizes use of another preparation in the same way.
An ingredient statement belongs to the named UK preparation
The same Utrogestan product information identifies soya lecithin and contains soya or peanut allergy restrictions. Those are product-specific details, not a complete description of every medicine containing progesterone. Nor can the ingredients of the separate US Prometrium product be substituted for the UK list. The practical step is to obtain the exact proposed product information and have a pharmacist address any ingredient concern. We do not determine allergy suitability. The bioidentical approval guide explains why identity language cannot settle either excipients or the applicable country’s regulatory status.
The advertised amounts pay for identified appointment categories
On Newson’s public appointment cards, the professional category changes the fee. The doctor option costs £295 for a first appointment; returning doctor consultations are priced at £230. A nurse or pharmacist appointment is advertised at £195 initially and £165 for a return visit. These amounts distinguish professional and appointment categories; they are not capsule prices. They also do not establish that tests, medicines or subsequent care are included in the consultation fee. Confirm the complete selected arrangement, including prescribing administration, pharmacy charges and booking or cancellation conditions. We have not tested those transactions or determined whether another clinician or an NHS service would accept responsibility for later prescribing. The advertised appointment can be priced while the eventual treatment remains undecided.
Do not equate a UK product description with a US compounding pathway
Our Thrivelab review examines an expressly compounded US pathway. Newson’s consultation description and the separate UK medicine record answer different questions under different arrangements. FDA’s compounding explanation is relevant to the US comparison, but it does not itself determine the status of a UK prescription or clinic. The comparison is useful for recognizing which document is missing, not for constructing a cross-border substitute. A body-identical description, an oral product label and a provider consultation are three separate pieces of information. None should be used to conceal the jurisdictional and clinical limits of the others.
A product-level answer should come from the actual clinical proposal
The unresolved question is not whether Newson discusses progesterone; its published service clearly does. It is which preparation, if any, the clinician would propose, for what purpose and under which continuing-care and pharmacy arrangements. Ask for that explanation with the medicine’s own patient information. A named label can then be read in the context of the proposal rather than used to guess it. This review confirms a UK hormone-care service and differentiated consultation fees, while leaving the exact micronised product unverified. It offers no individualized dosing, route change, approval equivalence or expectation that a consultation guarantees a prescription.
Documents behind the details
Read the source for the product, use and context it actually describes. A source type is not a rating of a provider.
- Newson Clinic: ConsultationsUK clinical assessment service; no exact oral medicine, individual eligibility or later NHS prescribing agreement confirmed · Checked 2026-09-29
- Newson Clinic: Menopause care and appointment pricesUK provider service, locations and clinician-specific initial/follow-up price cards; appointment fees are not medicine prices · Checked 2026-09-29
- Besins Healthcare UK: Utrogestan 100 mg Capsules, SmPCManufacturer UK product information hosted by emc, last updated March 19, 2025; exact oral product indication and soya/peanut contraindication, not Newson availability · Checked 2026-09-29
- NHS: About Utrogestan, micronised progesteroneUK public health medicine information, last reviewed January 5, 2023; oral HRT and vaginal fertility forms are distinguished, not interchangeable instructions · Checked 2026-09-29
- FDA: Prometrium progesterone capsules prescribing informationExact FDA product label, reference ID 5744934; ingredients, indications and warnings apply to this product, not all progesterone preparations · Checked 2026-09-29
- FDA: Understanding the Risks of Compounded DrugsFederal primary guidance on compounding and lack of FDA premarket approval; not individual treatment advice · Checked 2026-09-29